Anti-ACHA7/ CHRNA7/ CHRNA7-2 monoclonal antibody
Anti-ACHA7/ CHRNA7/ CHRNA7-2 antibody for FACS & in-vivo assay
Go to CHRNA7/CHRNA7 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T34429-Ab-1/ GM-Tg-hg-T34429-Ab-2 | Anti-Human CHRNA7 monoclonal antibody | Human |
GM-Tg-rg-T34429-Ab-1/ GM-Tg-rg-T34429-Ab-2 | Anti-Rat CHRNA7 monoclonal antibody | Rat |
GM-Tg-mg-T34429-Ab-1/ GM-Tg-mg-T34429-Ab-2 | Anti-Mouse CHRNA7 monoclonal antibody | Mouse |
GM-Tg-cynog-T34429-Ab-1/ GM-Tg-cynog-T34429-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CHRNA7 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T34429-Ab-1/ GM-Tg-felg-T34429-Ab-2 | Anti-Feline CHRNA7 monoclonal antibody | Feline |
GM-Tg-cang-T34429-Ab-1/ GM-Tg-cang-T34429-Ab-2 | Anti-Canine CHRNA7 monoclonal antibody | Canine |
GM-Tg-bovg-T34429-Ab-1/ GM-Tg-bovg-T34429-Ab-2 | Anti-Bovine CHRNA7 monoclonal antibody | Bovine |
GM-Tg-equg-T34429-Ab-1/ GM-Tg-equg-T34429-Ab-2 | Anti-Equine CHRNA7 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T34429-Ab-1/ GM-Tg-hg-T34429-Ab-2; GM-Tg-rg-T34429-Ab-1/ GM-Tg-rg-T34429-Ab-2; GM-Tg-mg-T34429-Ab-1/ GM-Tg-mg-T34429-Ab-2; GM-Tg-cynog-T34429-Ab-1/ GM-Tg-cynog-T34429-Ab-2; GM-Tg-felg-T34429-Ab-1/ GM-Tg-felg-T34429-Ab-2; GM-Tg-cang-T34429-Ab-1/ GM-Tg-cang-T34429-Ab-2; GM-Tg-bovg-T34429-Ab-1/ GM-Tg-bovg-T34429-Ab-2; GM-Tg-equg-T34429-Ab-1/ GM-Tg-equg-T34429-Ab-2 |
Products Name | Anti-CHRNA7 monoclonal antibody |
Format | mab |
Target Name | CHRNA7 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CHRNA7 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species ACHA7/ CHRNA7/ CHRNA7-2 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | vGMLP001474 | human CHRNA7 Lentivirus particle |
ORF Viral Vector | pGMLP001474 | human CHRNA7 Lentivirus plasmid |
ORF Viral Vector | pGMLPm005053 | mouse Chrna7 Lentivirus plasmid |
ORF Viral Vector | vGMLPm005053 | mouse Chrna7 Lentivirus particle |
Target information
Target ID | GM-T34429 |
Target Name | CHRNA7 |
Gene ID | 1139,25302,574230,488696,751113 |
Gene Symbol and Synonyms | BTX,CHRNA7,CHRNA7-2,NACHRA7,NARAD,nica7 |
Uniprot Accession | P36544,Q05941,Q866A2 |
Uniprot Entry Name | ACHA7_HUMAN,ACHA7_MACMU,ACHA7_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000175344 |
Target Classification | Ion Channel |
The target: CHRNA7, gene name: CHRNA7, also named as CHRNA7-2, NACHRA7. The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are thought to be hetero-pentamers composed of homologous subunits. The proposed structure for each subunit is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. The protein encoded by this gene forms a homo-oligomeric channel, displays marked permeability to calcium ions and is a major component of brain nicotinic receptors that are blocked by, and highly sensitive to, alpha-bungarotoxin. Once this receptor binds acetylcholine, it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. This gene is located in a region identified as a major susceptibility locus for juvenile myoclonic epilepsy and a chromosomal location involved in the genetic transmission of schizophrenia. An evolutionarily recent partial duplication event in this region results in a hybrid containing sequence from this gene and a novel FAM7A gene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.